» Articles » PMID: 38093983

Insulin Infusion Sets Associated with Adverse Events: Strategies for Improved Diabetes Education

Abstract

Introduction: Insulin Infusion Sets (IIS) play a crucial role in ensuring the safe delivery of insulin through a Continuous Subcutaneous Insulin Infusion (CSII) for individuals with Type 1 Diabetes (T1D). Recent advancements in therapy have highlighted the need to address issues such as unexplained hyperglycemia and IIS occlusion.

Objective: To investigate the adverse events (AEs) associated with IIS that impact the treatment of T1D, with a specific focus on promoting effective educational practices.

Methods: One hundred and eighteen patients under treatment at the Diabetes Center Insulin Pump Ambulatory, Federal University of São Paulo responded to a semi-structured questionnaire. Over 6 months, a nurse researcher interviewed them via video calls.

Results: Catheter-related adverse events (AEs) included catheter knots, folding, and accidental traction. AEs associated with cannula use were mainly related to cannula fixation adhesive, insulin leakage, bleeding episodes, and skin problems. The cannula patch tends to detach easily in hot conditions or when used for more than 3 days, leading to local itching. Adhesive glue can cause redness and pain. Insulin leakage typically occurs after the catheter disconnects from the cannula, accidental cannula traction, or beneath the cannula patch. Bleeding has been reported inside the cannula or at the insertion site, resulting in local pain and, in some cases, obstruction of insulin flow. When accidental cannula traction occurs, it is recommended to replace the entire IIS system. In situations involving bleeding, leakage, insulin odor, or unsuccessful attempts to correct hyperglycemic episodes with a "bolus" of insulin, it is advisable to change the IIS system and evaluate appropriate techniques for handling and infusing the device. Moreover, regular inspections of the device and reservoir/cartridge are essential.

Conclusion: Serious AEs can occur even in cases where the occlusion alarm is not activated, leading to interruptions in insulin flow. Conversely, in less severe situations, alarm activation can occur even in the absence of insulin flow interruption. Accidental catheter traction and catheter bending are commonly encountered in everyday situations, while issues related to the cannula directly affect blood glucose levels. AEs related to the IIS cannula often involve insulin leakage into the skin, bleeding, and skin events attributed to adhesive issues with the cannula.

Citing Articles

Does the Type of Cannula Matter? A Case Report and Review of the Evidence Regarding Steel and Plastic Cannulae With Respect to a Continuous Subcutaneous Insulin Infusion.

Barnett M, Prater J, Green L, Mayrin J Cureus. 2024; 16(11):e73900.

PMID: 39575358 PMC: 11580818. DOI: 10.7759/cureus.73900.


Time to Moderate and Severe Hyperglycemia and Ketonemia Following an Insulin Pump Occlusion.

Klonoff D, Ayers A, Ho C, Fabris C, Villa-Tamayo M, Allen E J Diabetes Sci Technol. 2024; 18(6):1472-1479.

PMID: 39240028 PMC: 11531023. DOI: 10.1177/19322968241280386.


Severe Insulin Pump-Related Adverse Events: Potential Root Causes and Impact of the COVID-19 Pandemic.

Orbell S, Codario R, Zupa M, Estock J J Diabetes Sci Technol. 2024; 19322968241254521.

PMID: 38804542 PMC: 11571623. DOI: 10.1177/19322968241254521.


Development of a Real-time Force-based Algorithm for Infusion Failure Detection.

Blanco L, Wilcox J, Hughes M, Lal R J Diabetes Sci Technol. 2024; 18(6):1313-1323.

PMID: 38654491 PMC: 11535327. DOI: 10.1177/19322968241247530.

References
1.
Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

2.
Clausen T, Kaastrup P, Stallknecht B . Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther. 2009; 11(9):575-80. DOI: 10.1089/dia.2009.0058. View

3.
Bonato L, Taleb N, Gingras V, Messier V, Gobeil F, Menard J . Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous Insulin Infusion: A Review. Diabetes Technol Ther. 2018; 20(7):506-515. DOI: 10.1089/dia.2018.0110. View

4.
Kerr D, Morton J, Whately-Smith C, Everett J, Begley J . Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2009; 2(3):450-5. PMC: 2769745. DOI: 10.1177/193229680800200314. View

5.
Ross P, Gray A, Milburn J, Kumarasamy I, Wu F, Farrand S . Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta Diabetol. 2016; 53(6):991-998. DOI: 10.1007/s00592-016-0897-2. View